Study details
Enrolling now
A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Rochester Center for Behavioral Medicine
NCT IDNCT06248229ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
50
Study length
about 2.2 years
Ages
18–65
Locations
1 site in MI
About this study
Researchers are testing whether Dyanavel XR can reduce fatigue symptoms in adults with ADHD compared to a placebo. The trial will last for 821 days and involve approximately 50 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Dyanavel XR
- 2.Take Placebo
PhasePhase 4
Primary goalFatigue Symptom Inventory (FSI)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Fatigue Symptom Inventory (FSI)
Secondary: ADHD Quality of Life Scale (ADHDQOL), Epworth Sleepiness Scale (ESS), Insomnia Severity Index (ISI)
Body systems
Psychiatry / Mental Health